RESUMO
The anabolic effect of parathyroid hormone (PTH) on bone is partly due to a stimulation of osteoblast proliferation. The PTH signal is transduced by the pathways of adenylyl cyclase (AC)/protein kinase (PK) A and phospholipase C/PKC/Ca++. There is still uncertainty about the relative contribution of the two pathways to the proliferative effects of the hormone. In our study, PTH(1-34), AC/PKA agonists, and phorbol 12-myristate-13-acetate (PMA, a PKC activator) stimulated cell proliferation in cultured mouse calvariae. In isolated osteoblasts, only PMA stimulated proliferation, whereas AC/PKA agonists and PTH(1-34) inhibited it. As already known, PTH in the presence of supramaximal concentrations of transforming growth factor-beta (TGF-beta) stimulated osteoblast growth; under these same conditions, AC/PKA agonists reproduced the stimulatory effect of PTH(1-34), whereas PMA became inhibitory. PTH(1-31), which stimulates AC without affecting PKC, acted similarly to the fully active PTH(1-34) in both calvaria and isolated osteoblasts. On the contrary, midregion fragments that activate only PKC stimulated calvaria cell proliferation faintly in comparison with PTH(1-34); no effect was seen in osteoblasts, either with or without TGF-beta. Our study shows that the effects of PTH on proliferation can be mimicked by agonists of the AC/cAMP pathway. Although PMA is indeed able to stimulate cell growth in tissue explants, its effects on isolated osteoblasts markedly diverge from those of PTH. We conclude that activation of the AC/PKA pathway is the main component of the proliferative effects of PTH.
Assuntos
Adenilil Ciclases/metabolismo , Osteoblastos/efeitos dos fármacos , Hormônio Paratireóideo/farmacologia , Proteína Quinase C/metabolismo , Transdução de Sinais/efeitos dos fármacos , 1-Metil-3-Isobutilxantina/farmacologia , Sequência de Aminoácidos , Animais , Divisão Celular/efeitos dos fármacos , Células Cultivadas , Colforsina/farmacologia , Técnicas de Cultura , Ativação Enzimática , Camundongos , Camundongos Endogâmicos ICR , Dados de Sequência Molecular , Osteoblastos/citologia , Fragmentos de Peptídeos/farmacologia , Teriparatida , Acetato de Tetradecanoilforbol/farmacologiaRESUMO
We report on the synthesis and the pharmacological properties of a new series of tachykinin antagonists based on the pseudopeptide pharmacophore cyclo[-Abo-Asp(D-Trp-Phe-N(Me)Bzl)-] which contains the 2-azabicyclo[2.2.2]octane-3(S)-carboxylic acid (Abo) residue. Variation of the substituents on the tryptophan indole nitrogen was shown to modulate water solubility and transport properties of the analogs as well as potency in classical in vitro response and binding assays. One water-soluble compound, 16, in which the substituent was 3-carbonylpropionate, strongly prolonged the reaction time in the mouse hot-plate test both after iv or oral administration and was devoid of degranulating activity in rat peritoneal mast cells.
Assuntos
Peptídeos Cíclicos/síntese química , Taquicininas/antagonistas & inibidores , Analgésicos/síntese química , Analgésicos/farmacologia , Animais , Ligação Competitiva , Encéfalo/metabolismo , Degranulação Celular/efeitos dos fármacos , Fenômenos Químicos , Físico-Química , Técnicas In Vitro , Camundongos , Peptídeos Cíclicos/química , Peptídeos Cíclicos/metabolismo , Peptídeos Cíclicos/farmacologia , Coelhos , Ratos , Receptores da Neurocinina-1 , Receptores da Neurocinina-2 , Receptores de Neurotransmissores/efeitos dos fármacos , Receptores de Neurotransmissores/metabolismo , Vasoconstrição/efeitos dos fármacosRESUMO
Since tachykinins released from lung sensory nerve endings are thought to play a role in inflammatory diseases of airways via NK1 and NK2 receptors, dual tachykinin NK1 and NK2 receptor antagonists may have a great therapeutic potential. In vitro, the cyclopeptide S 16474 (cyclo-[Abo-Asp(D-Trp(Suc0Na)-Phe-N-(Me)Bzl)]) bound to both human tachykinin NK1 and NK2 receptors expressed in two lines of transfected Chinese hamster ovary cells (IC50 values 85 nM and 129 nM, respectively), while showing a poor affinity for the rat tachykinin NK1 receptor. S 16474 inhibited the contractions induced by substance P in isolated rabbit vena cava (pA2 7.0) and by neurokinin A in rabbit pulmonary artery (pA2 5.6). In vivo in anaesthetized guinea-pigs, S 16474 was found to dose dependently inhibit the bronchoconstrictions induced by intravenously administered substance P, neurokinin A and capsaicin. Plasma extravasation evoked in bronchi by endogenously released tachykinins under vagus nerve stimulation was abolished by S 16474 (10 mu mol/kg i.v.). These results demonstrate clearly that S 16474 is a tachykinin receptor antagonist exhibiting, in vitro and in vivo, a dual inhibitory effect on NK1 and NK2 receptors.
Assuntos
Antagonistas dos Receptores de Neurocinina-1 , Oligopeptídeos/farmacologia , Receptores da Neurocinina-2/antagonistas & inibidores , Animais , Broncoconstrição/efeitos dos fármacos , Permeabilidade Capilar/efeitos dos fármacos , Degranulação Celular/efeitos dos fármacos , Cobaias , Humanos , Técnicas In Vitro , Masculino , Mastócitos/efeitos dos fármacos , Mastócitos/fisiologia , Oligopeptídeos/metabolismo , Coelhos , Ratos , Ratos Sprague-Dawley , Receptores da Neurocinina-1/metabolismo , Receptores da Neurocinina-2/metabolismo , Salivação/efeitos dos fármacos , Substância P/farmacologiaRESUMO
The potassium salt of a chemically stabilized dipeptide, {1-[4-(1 H-tetrazol-5-yl)butyl]indol-3-yl}carbonyl-Hyp-Nal-N(methyl)-Bzl , (Hyp = (R)-4-hydroxy-L-proline; Nal = 3-L-(beta-naphthyl)-alanine), S18523, is described as a new water-soluble, potent and selective NK1 receptor antagonist. The low molecular weight antagonist (M(r) = 736) displays nanomolar potency (pA2 = 9.6) in the rabbit vena cava (NK1) bioassay and nanomolar affinity (pKi = 9.1) on the human NK1 receptor expressed by lymphoblastoma cells. It is devoid of mu-opiate affinity (Ki > 10(-4) M with respect to tritiated Tyr-DAla-Gly-MePhe-Gly-ol), has negligible calcium-channel affinity (estimated Ki = 2.6 x 10(-5) M, with respect to isradipine) and does not cause peritoneal mast-cell degranulation. S18523 has strong antinociceptive effects in three classical pain tests in vivo both by i.v. and p.o. routes. The dipeptide potently antagonizes bronchoconstriction provoked by exogenous substance P in the guinea-pig and acts longer than the non-peptide antagonist CP99994, when administered as aerosol. Finally, S18523 displays antiinflammatory properties, since it dose-dependently inhibits substance P-induced plasma extravasation both in the bladder (ID50 = 0.18 mg/kg i.v.) and bronchi (ID50 = 0.14 mg/kg i.v.) of the guinea-pig.
Assuntos
Dipeptídeos/farmacologia , Antagonistas dos Receptores de Neurocinina-1 , Tetrazóis/farmacologia , Animais , Broncoconstrição/efeitos dos fármacos , Linhagem Celular/efeitos dos fármacos , Dipeptídeos/sangue , Dipeptídeos/síntese química , Dipeptídeos/metabolismo , Relação Dose-Resposta a Droga , Feminino , Cobaias , Técnicas In Vitro , Masculino , Camundongos , Medição da Dor/efeitos dos fármacos , Piperidinas/farmacologia , Coelhos , Ratos , Receptores da Neurocinina-1/sangue , Receptores da Neurocinina-1/metabolismo , Substância P/farmacologia , Tetrazóis/sangue , Tetrazóis/síntese química , Tetrazóis/metabolismoRESUMO
The stability and biotransformation of D-penicillamine as it relates to assay development is discussed. A review of published literature on assays is presented with respect to blood/plasma levels of D-penicillamine in man and to statistical evaluation of assays. Also, the paper describes gas chromatographic assay for D-penicillamine disulfide and L-cysteine D-penicillamine disulfide in urine and plasma, as well as a new high performance liquid chromatography assay for D-penicillamine in plasma.
Assuntos
Penicilamina/metabolismo , Bioensaio/métodos , Cromatografia Gasosa , Cromatografia Líquida de Alta Pressão , Humanos , Penicilamina/sangue , Penicilamina/urinaRESUMO
A model for the lower limit of quantitation for biomedical chromatographic assays is proposed. It is based on the IUPAC definition for the limit of detection and can be estimated from assay calibration data. It has been applied to ten different sets of calibration data from various assays of drugs in biological matrices.
Assuntos
Cromatografia/normas , Preparações Farmacêuticas/análise , Animais , Cromatografia Líquida de Alta Pressão , Cães , Cobaias , Humanos , Pulmão/química , Modelos Biológicos , Miocárdio/química , Ratos , Padrões de Referência , Espectrometria de Fluorescência , Espectrofotometria UltravioletaRESUMO
In general assays pertaining to drug level monitoring (DLM) of antiasthmatic agents (except theophylline), published during the period 1978-1983, used mostly high-performance liquid chromatographic (HPLC) methodology (approximately 45%) with mass spectrometric (MS) based assays in second place (approximately 30%) followed by immunochemical techniques (approximately 25%). Whenever nanogram or subnanogram antiasthmatic drug concentrations had to be measured such as for the adrenergic stimulants or for the prophylactic agents, then both HPLC-and MS-based methodologies were employed with about equal frequency. The trend in DLM for the phosphodiesterase inhibitor class (theophyllines) seemed to be shifting towards the HPLC methodologies. In part, this was justified by the need for improved selectivity. This criterion appears to have been better satisfied by HPLC, but for all practical purposes the immunochemical methods are and will probably continue to prevail in the clinical laboratory setting until HPLC procedures become truly automated. In the case of DLM of corticosteroids used for the asthmatic, the situation is in our opinion still unclear. This is caused by the presence of endogenous corticosteroids and metabolites, the levels of which in man are known to vary. The current immunochemical procedures offer a facile but less selective option. The future for selective routine corticosteroid assays may well be in HPLC or gas chromatography coupled with MS.
Assuntos
Asma/tratamento farmacológico , Corticosteroides/sangue , Agonistas Adrenérgicos beta/sangue , Asma/prevenção & controle , Cromatografia , Cromolina Sódica/sangue , Humanos , Cetotifeno/sangue , Monitorização Fisiológica , Parassimpatolíticos/sangue , Inibidores de Fosfodiesterase/sangueRESUMO
Biotransformation of 7-(3-[2-(3,5-dihydroxyphenyl)-2-hydroxy-ethylamino]-propyl)-theophylline (reproterol, Bronchospasmin), a beta 2-adrenergic drug recently introduced into therapeutic use, leads to the same main metabolite in animals and in man. By mass-spectroscopy and by synthesis its structure was shown to be tetrahydroisoquinoline derivative which is produced from reproterol by uptake of an additional carbon atom concomitant with cyclization.
Assuntos
Agonistas Adrenérgicos beta/metabolismo , Metaproterenol/análogos & derivados , Teofilina/análogos & derivados , Agonistas Adrenérgicos beta/síntese química , Animais , Bile/metabolismo , Biotransformação , Cromatografia Líquida de Alta Pressão , Cromatografia em Camada Fina , Eletroforese , Espectrometria de Massas , Metaproterenol/síntese química , Metaproterenol/metabolismo , Ratos , Teofilina/síntese química , Teofilina/metabolismoRESUMO
The major metabolite of reproterol (Broncho-spasmin) in rat feces is 2-[3-theophyllinyl(7)-propyl]-4,6,8-trihydroxy-1,2,3,4-tetrahydroisoquinoline. It was also found in the bile of orally or intravenously dosed rats in the form of glucuronides. The biotransformation of an oral dose of reproterol to this metabolite occurred mostly in the cecum-colon section of the intestinal tract. Experiments in antibiotic treated rats showed no significant effect of the treatment on the extent of metabolite formation. This metabolite was also formed by incubation of reproterol with cecum-colon homogenates under aerobic as well as anaerobic conditions. The pharmacological action after an oral dose must be attributed to reproterol absorbed as intact form, since the metabolite is inactive.
Assuntos
Fenômenos Fisiológicos do Sistema Digestório , Metaproterenol/análogos & derivados , Teofilina/análogos & derivados , Animais , Bile/análise , Biotransformação , Colo/fisiologia , Combinação de Medicamentos , Fezes/análise , Glucuronatos/metabolismo , Masculino , Metaproterenol/análise , Metaproterenol/metabolismo , Metaproterenol/urina , Ratos , Teofilina/análise , Teofilina/metabolismo , Teofilina/urinaRESUMO
3-Methyl-2,3-dihydro-9H-isoxazolo[3,2-b]quinazolin-9-one was readily absorbed, metabolized and eliminated in rat, dog, monkey and man. The radioactivity elimination after i.v. or p.o. administration of W-2451-14C in rats was biphasic with corresponding half-lives of 1.8 and 8.7 hours. Plasma half-lives of W-2451 in the dog, rhesus monkey and man were 1.4, 1.2 and 3.2 hours, respectively. In the rat, excretion via the urine was predominant, no significant accumulation in tissue occurred. The only major metabolite found in rat and dog urine, rat plasma and in the rat liver 9000 g supernatant fraction was the 3-hydroxy derivative of the drug. The unsaturated compound with the double bond in the 2,3-position and other hydroxylated metabolites were also present. Very little free or conjugated anthranilic acid and 3-(o-carboxy-phenylimino)-4-methylisoxazolidine were found.
Assuntos
Analgésicos/metabolismo , Isoxazóis/metabolismo , Oxazóis/metabolismo , Quinazolinas/metabolismo , Analgésicos/sangue , Analgésicos/urina , Animais , Biotransformação , Proteínas Sanguíneas/metabolismo , Cães , Haplorrinos , Humanos , Técnicas In Vitro , Isoxazóis/sangue , Isoxazóis/urina , Fígado/metabolismo , Masculino , Quinazolinas/sangue , Quinazolinas/urina , Ratos , Especificidade da Espécie , Fatores de Tempo , Distribuição TecidualRESUMO
Two major and one minor metabolite of felbamate (FBM) as well as unchanged drug were isolated and identified by electron impact and chemical ionization mass spectrometry from rat and dog urine after dosing with [14C]FBM. The metabolites were 2-(4-hydroxyphenyl)-1,3-propanediol dicarbamate (p-OHF), 2-hydroxy-2-phenyl-1,3-propanediol dicarbamate, and 2-phenyl-1,3-propanediol monocarbamate. The metabolites and FBM were excreted mainly in urine, where their sum accounted to 81-94% of the radioactivity in hydrolyzed rat urine samples, 71-82% in rabbit urine samples, and 69-83% in dog urine samples. The amount of metabolites in the conjugated form was estimated to be 20-35% in rat, 20-30% in rabbit, and 10-20% in dog urine. The major biliary metabolite in all three species was p-OHF, whereas the amount of FBM was small. Metabolites found in dog feces were the same as those in the urine.
Assuntos
Anticonvulsivantes/metabolismo , Propilenoglicóis/metabolismo , Animais , Anticonvulsivantes/urina , Bile/metabolismo , Radioisótopos de Carbono , Cães , Fezes/química , Felbamato , Espectrometria de Massas , Fenilcarbamatos , Propilenoglicóis/urina , Coelhos , RatosRESUMO
Rats, rabbits, and dogs were given single iv or single and multiple oral doses of felbamate ranging from 1.6-1000 mg/kg. Absorption of oral drug was complete in all species. The mean Cmax increased with dose from 13.9 to 185.9 micrograms/ml in rats, from 19.1 to 161.9 micrograms/ml in rabbits, and from 12.6 to 168.4 micrograms/ml in dogs. The tmax also increased with dose from 1-8 hr in rats, 8-24 hr in rabbits, and 3-7 hr in dogs. The plasma elimination half-life for the drug increased with dose from 2-16.7 hr in rats, 7.2-17.8 hr in rabbits, and 4.1-4.5 hr in dogs. A proportional increase in Cmax with dose was observed in all species up to 300-400 mg/kg doses. A biexponential equation fitted the drug plasma concentration vs. time data well. For multiple oral doses of 50 mg/kg or less, projected and observed steady-state concentrations agreed well. Animals dosed with [14C]felbamate eliminated most of the radioactivity in urine (58-87.7%), less in feces (7-23.7%), with considerable amounts in the bile. In rats, radioactivity was readily distributed into tissues and crossed the placenta and blood-brain barrier, but no accumulation in any tissue was observed. The volume of distribution was 131, 54, and 72% of body weight for rats, rabbits, and dogs, respectively. Binding of drug to rat, rabbit, and dog plasma proteins ranged from 22.4-35.9%. The overall plasma clearance of the drug for rats, rabbits, and dogs was 327, 52, and 108 ml.h-1.kg-1, respectively. Renal clearance of unchanged drug accounted for an estimated 20-35% and hepatic clearance due to metabolism for 65-80% of the overall clearance.
Assuntos
Anticonvulsivantes/farmacocinética , Propilenoglicóis/farmacocinética , Administração Oral , Animais , Anticonvulsivantes/metabolismo , Anticonvulsivantes/toxicidade , Cães , Felbamato , Feminino , Absorção Intestinal , Dose Letal Mediana , Masculino , Fenilcarbamatos , Gravidez , Propilenoglicóis/metabolismo , Propilenoglicóis/toxicidade , Ligação Proteica , Coelhos , Ratos , Ratos Endogâmicos , Distribuição TecidualRESUMO
Incubation of [14C]felbamate at 37 degrees C for 60 min with liver microsomes from untreated Sprague-Dawley rats converted 10% of the drug to the p-hydroxy (6%) and 2-hydroxy (4%) metabolites. With microsomes from phenobarbital-pretreated rats, 21% of the drug was metabolized to the p-hydroxy (7.5%) and 2-hydroxy (13.5%) metabolites. With microsomes from felbamate-pretreated rats, up to 25% of drug was metabolized to the p-hydroxy (5%) and 2-hydroxy (20%) metabolites. In addition, a small amount of the monocarbamate metabolite was also present, but no other metabolites were formed. Coincubations of [14C]phenytoin with felbamate had no effect on the metabolism of phenytoin, whereas the amount of [14C]felbamate metabolized in the presence of phenytoin decreased by 30-38%.
Assuntos
Anticonvulsivantes/metabolismo , Microssomos Hepáticos/metabolismo , Propilenoglicóis/metabolismo , Animais , Anticonvulsivantes/farmacologia , Interações Medicamentosas , Felbamato , Hidroxilação , Masculino , Fenobarbital/farmacologia , Fenilcarbamatos , Fenitoína/metabolismo , Fenitoína/farmacologia , Propilenoglicóis/farmacologia , Ratos , Ratos Endogâmicos , Fatores de TempoRESUMO
A mechanistic investigation of the inactivation of Escherichia coli glucosamine-6-phosphate synthase by N3-(4-methoxyfumaroyl)-L-2,3-diaminopropionate (FMDP) was undertaken. On the basis of the known participation of the N-terminal cysteine residue in this process [Chmara et al. (1986) Biochim. Biophys. Acta 870, 357; Badet et al. (1988) Biochemistry 27, 2282], the model reactions between FMDP and L-cysteine and between FMDP and the synthetic decapeptide Cys-Gly-Ile-Val-Gly-Ala-Ile-Ala-Gln-Arg, corresponding to the amino-terminal protein sequence, were studied. The results allowed us to propose a pathway that is in perfect agreement with the biochemical results: enzyme inactivation arose from Michael addition of glutamine binding site cysteine-1 on the fumaroyl double bond at the beta-position of the ester group. Upon denaturation under slightly alkaline conditions, this adduct underwent cyclization to a transient succinimide adduct, which rearranged into the stable 2-substituted 1,4-thiazin-3-one-5-carboxylate involving participation of the cysteine amino group. The tryptic radiolabeled peptides purified from [3H]FMDP-treated enzyme and resistant to Edman degradation coeluted with the products resulting from the model reaction between the synthetic decapeptide and the inhibitor.
Assuntos
Alanina/análogos & derivados , Escherichia coli/enzimologia , Fumaratos/farmacologia , Glutamina-Frutose-6-Fosfato Transaminase (Isomerizante)/antagonistas & inibidores , Transaminases/antagonistas & inibidores , beta-Alanina/análogos & derivados , Sequência de Aminoácidos , Fenômenos Químicos , Química , Ativação Enzimática/efeitos dos fármacos , Fumaratos/análise , Glutamina-Frutose-6-Fosfato Transaminase (Isomerizante)/análise , Concentração de Íons de Hidrogênio , Cinética , Modelos Biológicos , Dados de Sequência Molecular , beta-Alanina/análise , beta-Alanina/farmacologiaRESUMO
Using a reproducible screening procedure for rat liver cytochrome P450 isoenzyme induction/inhibition, five dicarbamate drugs (meprobamate, mebutamate, carisoprodol, tybamate, and W-554) were compared with sodium phenobarbital and found to be from 25 to 100 times less potent hepatic cytochrome P450 inducers than phenobarbital.
Assuntos
Carbamatos/farmacologia , Sistema Enzimático do Citocromo P-450/biossíntese , Fígado/enzimologia , Fenobarbital/farmacologia , Animais , Carisoprodol/farmacologia , Relação Dose-Resposta a Droga , Indução Enzimática/efeitos dos fármacos , Masculino , Proteínas/análise , Ratos , Ratos EndogâmicosRESUMO
An automated, internal standard high-performance liquid chromatographic method for the simultaneous quantitation of felbamate and its three metabolites in adult and neonatal rat brain and heart tissue homogenates was developed and validated. The homogenates prepared from one part of the tissue and four parts of water were extracted with ethyl acetate, and the extract was evaporated to dryness and redissolved in mobile phase. Separation was accomplished on a Waters Resolve C18, 5 microns, 300 mm x 3.9 mm I.D. column with a mobile phase consisting of 0.01 M phosphate buffer, pH 6.8-acetonitrile-methanol (800:150:50, v/v/v). Eluting peaks were monitored with an ultraviolet detector at 210 nm. The linear range of the assay for felbamate and the metabolites was 0.20-50.00 micrograms/ml of homogenate or 1-250 micrograms/g of brain or heart tissue. The lower limit of quantitation for all four analytes was 0.20 micrograms/ml of homogenate or 1.00 micrograms/g of tissue.
Assuntos
Anticonvulsivantes/análise , Química Encefálica , Cromatografia Líquida de Alta Pressão/métodos , Miocárdio/química , Propilenoglicóis/análise , Propilenoglicóis/metabolismo , Envelhecimento , Animais , Animais Recém-Nascidos , Cromatografia Líquida de Alta Pressão/normas , Cromatografia Líquida de Alta Pressão/estatística & dados numéricos , Felbamato , Fenilcarbamatos , Ratos , Análise de RegressãoRESUMO
Felbamate (2-phenyl-1,3-propanediol dicarbamate) is a novel agent effective against maximal electroshock, pentylenetetrazol and other chemically induced seizures in mice and rats. Felbamate has been proposed as a novel anticonvulsant for the treatment of generalized tonic-clonic and complex partial seizures. In addition, felbamate has been shown to have neuroprotectant effects (in vitro and in vivo) in neonate models of cerebral ischemia. However, few existing studies have contributed to the elucidation of the mechanism of anticonvulsant and neuroprotectant action of felbamate. Because glycinergic mechanisms have been demonstrated to be involved with seizure disorders and neuroprotection, we investigated the binding interaction of felbamate with strychnine-insensitive glycine receptors and compared these findings with brain and plasma levels of felbamate after drug treatment. Inhibition of [3H]5,7-dichlorokynurenic acid (a high-affinity glycine receptor antagonist) binding by felbamate (IC50 = 374 microM) corresponded well with peak felbamate concentrations found in brain (683 and 759 microM) and plasma (679 and 807 microM) 8 hr after 300 (i.p.) or 500 mg/kg (p.o.) doses, respectively. Chemically diverse anticonvulsants tested and MK 801 [(+)-5-methyl-10,11-dihydro-5H-dibenzo-[a,d]cyclohepten-5,10-imine maleate] did not modulate [3H]5,7-dichlorokynurenic acid binding. Additional studies have shown that felbamate does not interact with other sites associated with the N-methyl-D-aspartate receptor complex. Thus, the data presented in this report strongly indicate a mechanism of action for felbamate through strychnine-insensitive glycine receptor interaction.
Assuntos
Anticonvulsivantes/farmacologia , Neurônios/efeitos dos fármacos , Propilenoglicóis/farmacologia , Receptores de Neurotransmissores/efeitos dos fármacos , Estricnina/farmacologia , Animais , Encéfalo/metabolismo , Maleato de Dizocilpina/metabolismo , Felbamato , Feminino , Técnicas In Vitro , Ácido Cinurênico/análogos & derivados , Ácido Cinurênico/metabolismo , Masculino , Fenilcarbamatos , Propilenoglicóis/farmacocinética , Ratos , Ratos Sprague-Dawley , Receptores de Glicina , Receptores de Neurotransmissores/fisiologiaRESUMO
Analytical methods have been developed for the simultaneous quantitation of azelastine (AZ) and desmethylazelastine (DAZ) in guinea pig plasma and lung tissue. The methods require a 1.00 mL plasma sample and a minimum 0.100 g lung sample. Both methods employ liquid/liquid organic extraction and back-extraction into dilute acid. Quantitation is performed by high performance liquid chromatography on a 2 x 250 mm 5 microns Hypersil CPS column using fluorescence detection. The linear quantitative ranges for AZ.HCl and DAZ.HBr in plasma are 0.156-160 ng/mL and 0.313-160 ng/mL, respectively. The linear quantitative ranges for AZ.HCl and DAZ.HBr in lung tissue are 0.039-20 micrograms/g for both.